Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert M. Feldman is active.

Publication


Featured researches published by Robert M. Feldman.


American Journal of Ophthalmology | 1998

Anterior uveitis associated with latanoprost

Robert D. Fechtner; Albert S. Khouri; Thom J. Zimmerman; John Bullock; Robert M. Feldman; Prasad S. Kulkarni; Andrew J. Michael; Tony Realini; Ronald E. Warwar

PURPOSE To report the association of anterior uveitis with the use of latanoprost. METHODS We studied four patients with complicated open-angle glaucoma who had anterior uveitis associated with the use of latanoprost. The uveitis was unilateral and occurred only in the eye receiving latanoprost in three patients. In one patient, latanoprost was used in both eyes, and the uveitis was bilateral. Four of five eyes had a history of prior inflammation and/or prior incisional surgery. All patients were rechallenged with the drug. RESULTS The uveitis improved after cessation of latanoprost with or without topical corticosteroids. It recurred after rechallenging with latanoprost in all eyes. CONCLUSION There is a possible association between latanoprost and anterior uveitis. Topical prostaglandin analogs may be relatively contraindicated in patients with a history of uveitis or prior ocular surgery. This association may also be possible in eyes that have not had previous uveitis or incisional surgery.


Ophthalmology | 1995

Intraocular Pressure Elevation Associated with Inhalation and Nasal Corticosteroids

Ira Opatowsky; Robert M. Feldman; Ronald L. Gross; Sandy T. Feldman

BACKGROUND The ocular hypertensive response to corticosteroids is well established. Elevated intraocular pressure (IOP) secondary to corticosteroids by nasal spray or inhalation has rarely been reported. RESULTS Three patients showed a possible ocular hypertensive response to beclomethasone dipropionate by nasal spray or inhalation. In two patients, the IOP returned to pretreatment levels after discontinuing nasal corticosteroid spray. One patient required medication to control IOP with continued inhaled corticosteroid. One patient later demonstrated an ocular hypertensive response to oral steroids. CONCLUSION Corticosteroids by nasal spray or inhalation may cause ocular hypertension in susceptible patients. The authors recommend surveillance of IOP in patients using these medications.


Journal of Ocular Pharmacology and Therapeutics | 2003

Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension.

Robert M. Feldman

The prostaglandin derivatives are thought to lower intraocular pressure (IOP) primarily by increasing uveoscleral outflow. The ocular side effect, hyperemia, appears to occur via a secondary, unrelated mechanism. Variations in the IOP-lowering effect and incidence of hyperemia associated with these drugs are a function of their different chemical structures. Among the currently approved prostaglandin derivatives, hyperemia occurs in as many as 50% of patients treated with travoprost and as few as 5% of patients treated with latanoprost. The side effect of hyperemia may be of concern to the ophthalmologist for at least 2 reasons: hyperemia may compromise the outcome of filtration surgery, and it may represent a cosmetic problem to the patient thereby leading to non-compliance. The extent to which hyperemia may contribute to patient noncompliance and the effect of administration of the prostaglandin derivatives on outcome of filtration surgery remain to be determined. Until more definitive data are available, when selecting a prostaglandin analogue for ocular hypotensive therapy, it seems prudent to choose an agent with a low incidence of hyperemia.


Ophthalmology | 1989

Risk factors for the development of Tenon's capsule cysts after trabeculectomy

Robert M. Feldman; Ronald L. Gross; George L. Spaeth; William C. Steinmann; Rohit Varma; L. Jay Katz; Richard P. Wilson; Marlene R. Moster; Detlev Spiegel

Tenons capsule cysts (TCCs) are a complication of glaucoma filtering surgery. They are frequently associated with substantial elevations in intraocular pressure (IOP) beginning 2 to 8 weeks postoperatively. To determine the incidence and possible risk factors for the development of TCCs, case records of all patients who received trabeculectomy over a 4-year period at the Wills Eye Hospital were reviewed. The incidence of TCCs was 28% in those who underwent trabeculectomy. Characteristics of patients after trabeculectomy in whom TCCs developed were compared with patients after trabeculectomy in whom TCCs did not develop. Both univariate and multivariate techniques were used to assess the association of characteristics associated with the development of TCCs. Factors associated with increased risk (P less than 0.05) were: history of prior TCCs, argon laser trabeculoplasty, male gender, and the use of preoperative sympathomimetics. The use of a compression shell was associated with decreased risk (P less than 0.05).


British Journal of Ophthalmology | 1998

Suramin inhibits wound healing following filtering procedures for glaucoma.

Holger Mietz; Patricia Chévez-Barrios; Robert M. Feldman; Michael W. Lieberman

BACKGROUND Trabeculectomies are the most frequently performed procedures in surgically treating eyes with glaucoma. Failures are caused by fibrosis in the external ostium of the filtering procedure. In order to inhibit the fibrotic wound healing reaction, a new pharmacological approach using suramin, which inhibits a variety of important growth factors was used. METHODS Pigmented rabbits were used and filtering procedures performed. Suramin was applied with concentrations ranging from 10 mg/ml to 333 mg/ml once during surgery and four times following surgery. The success of the filtering procedure was assessed by intraocular pressure measurements. To evaluate possible intraocular toxic effects, treated eyes were histopathologically evaluated after 4 weeks, and the ciliary body adjacent to the site of application was examined using electron microscopy. RESULTS With concentrations of suramin of 200 mg/ml and 333 mg/ml, the trabeculectomies were patent longer than in the controls and in eyes operated with mitomycin C, which currently is the most frequently used antiproliferative drug to enhance the outcome of surgery in humans. No severe toxic effects to the ciliary epithelium were seen in suramin treated eyes. CONCLUSIONS This study demonstrates for the first time the efficiency of a substance that broadly inhibits the action of growth factors on target cells in the setting of ocular wound healing. In this in vivo model, suramin has been shown to be highly effective in preventing scarring and in having fewer toxic side effects than usually used antimetabolites. These results therefore may suggest a new approach to the surgical treatment of glaucoma.


Ophthalmology | 1988

Surgical Therapy of Chronic Glaucoma in Aphakia and Pseudophakia

Ronald L. Gross; Robert M. Feldman; George L. Spaeth; William C. Steinmann; Detlev Spiegel; L. Jay Katz; Richard P. Wilson; Rohit Varma; Marlene R. Moster; Steven Marks

Most glaucoma surgical procedures are less successful in aphakic or pseudophakic eyes. The authors reviewed 91 consecutive initial glaucoma procedures in aphakic patients from 1979 to 1986 to determine successful outcomes and complications. Success was defined as an intraocular pressure (IOP) of at least 30% below the preoperative value and less than 21 mmHg, less than 2 lines of Snellen acuity loss, and no further surgical intervention. At 9 months, success rates were: trabeculectomy, 4 of 15 patients; cyclodialysis, 3 of 20 patients; neodymium:YAG (Nd:YAG) cyclophotocoagulation, 1 of 8 patients; cyclocryotherapy, 9 of 22 patients; anterior chamber tube shunt (Schocket procedure), 3 of 6 patients; and argon laser trabeculoplasty, 2 of 20 patients. Severe complications included phthisis bulbi in 11% of cyclocryotherapy and severe visual loss in 20% with cyclodialysis and 14% with cyclocryotherapy. Results confirm the difficulty of surgical therapy in these patients.


Current Opinion in Ophthalmology | 2008

Risk factors for primary open angle glaucoma progression: what we know and what we need to know

Jorge L Rivera; Nicholas P. Bell; Robert M. Feldman

Purpose of review Recent literature is reviewed in order to identify possible risk factors leading to primary open angle glaucoma progression and blindness. Recent findings Several risk factors have been suggested to be important for progression of open angle glaucoma. Intraocular pressure appears to be an important risk factor for progression of glaucoma. It is still not clear if intraocular pressure fluctuation and central corneal thickness are related to progression. Myopia might be related to glaucoma progression as well as optic disc hemorrhages. Vascular factors appear to be related to progression also. Genetics seem to play an important role in open angle glaucoma. Summary Identifying risk factors associated with progression of patients with primary open angle glaucoma is essential to our clinical practices. The level of understanding regarding those risks is suboptimal at this point. Prospective long-term studies are needed if we wish to better understand the disease and help those patients at greater risk of progression and blindness.


Retina-the Journal of Retinal and Vitreous Diseases | 1993

Visual outcome in acute retinal necrosis.

Joseph A. Crapotta; William R. Freeman; Robert M. Feldman; Careen Y. Lowder; John S. Ambler; Carol E. Parker; David M. Meisler

Abstract: Acute retinal necrosis (ARN) is generally a progressive retinitis, often complicated by retinal detachment and a poor visual outcome. A series of 12 consecutive patients (13 eyes) with ARN is reported. All patients were examined early, with a limited extent of disease (in 77% of the eyes, less than 25% of retina involved). Patients were treated with high-dose intravenous acyclovir (10 mg/kg every 8 hours) and laser photocoagulation. During a follow-up period of 3 to 21 months, only 1 patient developed a rhegmatogenous retinal detachment resulting in visual loss. No patients developed bilateral disease once intravenous antiviral therapy was begun. Final visual acuity was 20/40 or better in 6 eyes (46%), and 20/400 or better in 12 eyes (92%). Two patients were examined within 6 weeks of extracapsular cataract extraction with intraocular lens implantation. In the majority of the cases, clinical findings were limited to several quadrants of the peripheral retina. Eyes with limited disease, if aggressively treated, have a relatively good visual prognosis.


Ophthalmic Surgery and Lasers | 1998

A Randomized Double-Masked Trial Comparing Ketorolac Tromethamine 0.5%, Diclofenac Sodium 0.1%, and Prednisolone Acetate 1% in Reducing Post-Phacoemulsification Flare and Cells

Sherif M. El-Harazi; Richard S. Ruiz; Robert M. Feldman; Guillermina Villanueva; Alice Z. Chuang

BACKGROUND AND OBJECTIVE To compare the efficacy of ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing flare and cells following cataract surgery. PATIENTS AND METHODS Fifty-eight patients undergoing phacoemulsification with posterior chamber intraocular lens implantation were randomly selected to receive either ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, or prednisolone acetate 1% following surgery. The treatment regimen was 1 drop 4 times a day for 1 week, then twice a day for the next 3 weeks. Flare, cells, and intraocular pressures (IOPs) were measured preoperatively and on postoperative days 1, 7, and 28. RESULTS No statistically significant differences in either actual flare or cell counts or in change in flare or cell counts from baseline were detected among the three groups. No statistically significant differences in IOP or in change of IOP from preoperative measurements were detected. No medication-related complications were noted at any time. CONCLUSION Ketorolac tromethamine 0.5% and diclofenac sodium 0.1% may be as effective and as safe as prednisolone acetate 1% in controlling inflammation following cataract extraction.


Ophthalmology | 2002

Combined cataract extraction and Baerveldt glaucoma drainage implant indications and outcomes

Kara Hoffman; Robert M. Feldman; Donald L. Budenz; Steven J. Gedde; Grace Abou Chacra; Joyce C. Schiffman

PURPOSE To report the indications and outcomes of simultaneous cataract extraction (CE) and Baerveldt glaucoma drainage implant surgery. DESIGN Noncomparative, interventional, retrospective, consecutive case series. PARTICIPANTS Thirty-three eyes of 33 patients. INTERVENTION Combined phacoemulsification CE and Baerveldt glaucoma drainage implant (BGI) surgery at two tertiary care referral centers. MAIN OUTCOME MEASURES Visual acuity, intraocular pressure (IOP), and complications. RESULTS The study included 33 eyes of 33 patients followed for an average of 15.4 months (range, 3.0-46.9). The most common indication for combined CE and Baerveldt glaucoma drainage implant surgery was a history of prior failed trabeculectomy. Postoperative visual acuity at last follow-up was > or =20/40 in 12 of 33 patients (36%). IOP was reduced from a mean (+/- standard deviation) of 21 +/- 7.3 mmHg preoperatively to 13.1 +/- 3.5 mmHg at last follow-up visit ( P < 0.001). The number of antiglaucoma medications was reduced from a mean (+/- standard deviation) of 2.3 +/- 1.0 preoperatively to 0.7 +/- 1.1 at last follow-up (P < 0.001). Three eyes met our criteria for failure, and cumulative survival of the glaucoma surgery at 18 months was 89%. Intraoperative complications were all related to the cataract surgery, whereas early and late postoperative complications were related both to the CE and BGI surgery. CONCLUSIONS Combined CE and Baerveldt glaucoma drainage implant placement seems to be a safe and effective surgical option and may be preferred in certain clinical situations.

Collaboration


Dive into the Robert M. Feldman's collaboration.

Top Co-Authors

Avatar

Alice Z. Chuang

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Nicholas P. Bell

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Ronald L. Gross

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Sherif M. El-Harazi

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Laura A. Baker

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Guillermina Villanueva

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Donald L. Budenz

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

David A. Lee

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar

Kimberly A. Mankiewicz

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge